CHRNA7 and osteosarcoma: Moreover, osteosarcoma cells may express cholinergic components (e.g., α7 nicotinic receptors/CHRNA7 and choline-acetyltransferase), implying that α7nAChR-directed co-therapies could, context-dependently, affect proliferation and migration, warranting receptor profiling before combination testing.